

11/B
C.E.
3-17-01
PATENT

Customer Number 22,852
Attorney Docket No. 4995.0032-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jeffrey R. Stinson et al.

Serial No.: 09/215,163

Filed: December 18, 1998

For: HUMANIZED MONOCLONAL
ANTIBODIES THAT PROTECT
AGAINST SHIGA TOXIN
INDUCED DISEASE



Group Art Unit: 1645

Examiner: J. Graser

RECEIVED

MAR 15 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT

In reply to the Office Action dated December 14, 2000, please amend the application as follows:

IN THE CLAIMS:

Please amend claims 14, 15, 18, 19, 20 with the following revised claims, as follows:

14. (Amended) The humanized monoclonal antibody of claim 13, wherein said non-human variable region is from a mouse.

15. (Amended) The humanized monoclonal antibody of claim 13, wherein at least part of said variable region is from the sequence set forth in SEQ ID NO:42 and SEQ ID NO:44.

18. (Amended) The humanized monoclonal antibody of claim 17, wherein said human constant region is IgG.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000

19. (Amended) A humanized monoclonal antibody which binds Shiga toxin type 2 and Shiga toxin type 2 variants, comprising a constant region and a variable region, wherein:

said constant region is IgG1-kappa, and

said variable region contains at least part of the sequence as set forth in SEQ ID NO:42 and SEQ ID NO:44.

20. (Amended) A humanized monoclonal antibody which binds Shiga toxin type 2 and Shiga toxin type 2 variants, comprising a constant region and a variable region, wherein:

said constant region is IgG1-kappa, and

said variable region contains at least part of the CDR sequences, located as follows:

Heavy Chain CDRs: CDR1--aa31-35

(SEQ ID NO:44) CDR2--aa50-66

CDR3--aa99-108

Light Chain CDRs: CDR1--aa24-40

(SEQ ID NO:42) CDR2--aa56-62

CDR3--aa95-103.

REMARKS

Claims 1, 2, 13-20, 23, and 29 are currently under consideration, with claims 14, 15, 18, 19 and 20 amended as noted above. As set forth on the Appendix, these amendments are to correct antecedent basis and/or specify SEQ ID NOS. and are supported by the originally filed claims. As to the specifics of the Office Action, items 2-4 maintain rejections and introduce new rejections of the pending claims under § 112, first and second paragraphs. In item 5, the Office